{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:06:12Z","timestamp":1790802372157,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117015","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:44:38Z","timestamp":1788417878000},"page":"117015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?"],"prefix":"10.1016","volume":"247","author":[{"given":"Fabio","family":"Conforti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0883-0582","authenticated-orcid":false,"given":"Jacopo","family":"Canzian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Tinterri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Bendoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"De Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-4333","authenticated-orcid":false,"given":"Aldo","family":"Caltavituro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9064-0113","authenticated-orcid":false,"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Schettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-540X","authenticated-orcid":false,"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1882-7068","authenticated-orcid":false,"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8270-8712","authenticated-orcid":false,"given":"Richard","family":"Gelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117015_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1200\/OP.23.00563","article-title":"Tailoring neoadjuvant therapy in human epidermal growth factor receptor 2-positive early breast cancer: recent advances and strategies","volume":"20","author":"Esteva","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ejca.2026.117015_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.03.042","article-title":"Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis","volume":"190","author":"Villacampa","year":"2023","journal-title":"Eur J Cancer"},{"issue":"10437","key":"10.1016\/j.ejca.2026.117015_bib3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","volume":"403","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.117015_bib4","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(22)00159-0","volume":"23","author":"Nitz","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/jnci\/djh131","article-title":"Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer","volume":"96","author":"Pegram","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.117015_bib7","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.2005.04.1764","article-title":"Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer","volume":"24","author":"Robert","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117015_bib9","doi-asserted-by":"crossref","unstructured":"Slamon D.J., Eiermann W., Robert N.J., et al: Ten-year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive early breast cancer patients. 2015 San Antonio Breast Cancer Symposium. Abstract S5-04.","DOI":"10.1158\/1538-7445.SABCS15-S5-04"},{"key":"10.1016\/j.ejca.2026.117015_bib10","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib11","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","article-title":"Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial","volume":"7","author":"van der Voort","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2026.117015_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejca.2026.117015_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1007493","article-title":"Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression","volume":"15","author":"Anttila","year":"2019","journal-title":"PLoS Comput Biol"},{"issue":"3","key":"10.1016\/j.ejca.2026.117015_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"16","key":"10.1016\/j.ejca.2026.117015_bib15","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.117015_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.2010.28.6450","volume":"29","author":"Valero","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.117015_bib17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib18","article-title":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer","author":"Tolaney","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2026.117015_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2026.117015_bib20","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.20.03398","article-title":"Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial","volume":"39","author":"Tolaney","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib21","doi-asserted-by":"crossref","unstructured":"Untch, M. et al Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Annals of Oncology, Volume 28, v49.","DOI":"10.1093\/annonc\/mdx362.014"},{"key":"10.1016\/j.ejca.2026.117015_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103938","article-title":"Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06\/NCCTG N063D (Alliance)]","volume":"9","author":"de Azambuja","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.117015_bib23","article-title":"Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial","author":"Gao","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(24)00581-3","article-title":"De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial","volume":"26","author":"Chen","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib25","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.ejca.2026.117015_bib26","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1200\/JCO-24-01360","article-title":"Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer","volume":"43","author":"Conforti","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib27","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jamaoncol.2022.3755","article-title":"Surrogacy of pathologic complete response in trials of neoadjuvant therapy for early breast cancer: critical analysis of strengths, weaknesses, and misinterpretations","volume":"8","author":"Conforti","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.117015_bib28","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4143\/crt.2021.901","article-title":"Real World Evidence of Neoadjuvant Docetaxel\/Carboplatin\/Trastuzumab\/Pertuzumab (TCHP) in Patients with HER2-positive early or locally advanced breast cancer: a single-institutional clinical experience","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.ejca.2026.117015_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.27074","article-title":"Cost-effectiveness of neoadjuvant-adjuvant treatment strategies for women with ERBB2 (HER2)-Positive Breast Cancer","volume":"3","author":"Kunst","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.ejca.2026.117015_bib30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2006.06.3081","article-title":"A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2\/neu-positive breast cancer","volume":"25","author":"Kurian","year":"2007","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ejca.2026.117015_bib31","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.2217\/fon-2022-1282","article-title":"DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer","volume":"19","author":"Debien","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.501","article-title":"Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II\/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181\/CompassHER2 pCR trial","volume":"43","author":"Tung","year":"2025","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ejca.2026.117015_bib33","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.2217\/fon-2021-0753","article-title":"Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib\/placebo in patients with residual HER2-positive invasive breast cancer","volume":"17","author":"O'Sullivan","year":"2021","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.117015_bib34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"KATHERINE study group. survival with trastuzumab emtansine in residual HER2-Positive Breast Cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117015_bib35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","article-title":"Dissecting the biological heterogeneity of HER2-positive breast cancer","volume":"59","author":"Schettini","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2026.117015_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.ejca.2026.117015_bib37","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S1470-2045(20)30450-2","article-title":"A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117015_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-025-00753-8","article-title":"HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab","volume":"11","author":"S\u00e1nchez-Bayona","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.117015_bib39","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/jnci\/djac227","article-title":"HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1","volume":"115","author":"Bras\u00f3-Maristany","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ejca.2026.117015_bib40","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3390\/cancers12071902","article-title":"ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer","volume":"12","author":"Griguolo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.117015_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104320","article-title":"HER2DX genomic test in HER2-positive\/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial","volume":"85","author":"Guarneri","year":"2022","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.ejca.2026.117015_bib42","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.annonc.2023.05.012","article-title":"Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer","volume":"34","author":"Villacampa","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104465","article-title":"Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review","volume":"81","author":"Mu\u00f1oz","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2026.117015_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(25)00276-1","article-title":"HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis","author":"Villacampa","year":"2025","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.117015_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103987","article-title":"HER2DX genomic test in early-stage HER2-positive breast cancer","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.117015_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.607","article-title":"HER2DX genomic test in HER2-positive breast cancer treated with 15 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP): Final analysis from the BiOnHER clinical trial","volume":"43","author":"Fullana Grimalt","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib47","article-title":"Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study","volume":"8","author":"Mart\u00ednez-S\u00e1ez","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib48","doi-asserted-by":"crossref","unstructured":"Pascual T. et al. 149TiP DEFINITIVE TRIAL: Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer. ESMO Open, Volume 10, 104702.","DOI":"10.1016\/j.esmoop.2025.104702"},{"key":"10.1016\/j.ejca.2026.117015_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00031","article-title":"Homologous Recombination Deficiency in Breast Cancer: A Clinical Review","volume":"1","author":"den Brok","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib50","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","article-title":"Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","volume":"29","author":"Loibl","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib51","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.annonc.2021.09.003","article-title":"Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial","volume":"32","author":"Llop-Guevara","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221096253","article-title":"Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib53","article-title":"Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer","volume":"7","author":"Yndestad","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.117015_bib54","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ijc.29829","article-title":"Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas","volume":"138","author":"Mani\u00e9","year":"2016","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2026.117015_bib55","article-title":"Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers","volume":"30","author":"Evelyn","year":"2025","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejca.2026.117015_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104120","article-title":"Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges","volume":"10","author":"Schlam","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2026.117015_bib57","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2022.01.031","volume":"166","author":"Gelber","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117015_bib58","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.117015_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102903","article-title":"Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer","volume":"9","author":"Mar\u00edn-Aguilera","year":"2024","journal-title":"ESMO Open"},{"issue":"18","key":"10.1016\/j.ejca.2026.117015_bib60","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1158\/1078-0432.CCR-24-0464","article-title":"HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial","volume":"30","author":"Llombart-Cussac","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.ejca.2026.117015_bib61","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2013.53.7142","article-title":"Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0\u20133 positive axillary nodes: CALGB 40101 (Alliance)","volume":"32","author":"Shulman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ejca.2026.117015_bib62","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1200\/JCO.18.01842","article-title":"NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto","volume":"37","author":"Untch","year":"2019","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ejca.2026.117015_bib63","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial","volume":"S0923-7534","author":"Harbeck","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117015_bib64","unstructured":"Geyer C.E. Jr., Park Y.H., Shao, Z.-M., et al. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1). Interim analysis of DESTINY-Breast05. Annals of Oncology, 36(Suppl 2), Abstract LBA1."},{"key":"10.1016\/j.ejca.2026.117015_bib65","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211009003","article-title":"Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial","volume":"13","author":"Gao","year":"2021","journal-title":"Ther Adv Med Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:32:10Z","timestamp":1790800330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":65,"alternative-id":["S0959804926007963"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117015"}}